HC Wainwright maintains "buy" rating for Cogent Biosciences (COGT) with a $19.00 target, implying a 123.53% upside.

HC Wainwright reaffirmed its "buy" rating for Cogent Biosciences (NASDAQ: COGT) with a $19.00 price target, reflecting a potential 123.53% upside from the company's current price. Cogent Biosciences is a biotechnology company focused on developing precision therapies for genetically defined diseases, with its lead product candidate being bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor.